Exhibit 99.1

	NEWS RELEASE
Thomas E. Rathjen Vice President, Investor Relations 561-989-5800 | www.nabi.com

FOR IMMEDIATE RELEASE

Nabi Biopharmaceuticals Files Form 10-K and Corrects Financial Tables

Boca Raton, Florida, March 15, 2007 – Nabi Biopharmaceuticals (Nasdaq: NABI) announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 30, 2006 and re-released its 2006 fourth quarter and full-year financial results, correcting errors which appeared in its March 12, 2006 release originally announcing those results. These errors, which are corrected in the attached financial tables, primarily involved the allocation of the income tax provision for the fourth quarter of 2005 between continuing and discontinued operations, a correction to the fourth quarter 2006 basic and diluted loss per share from $0.07 to $0.06 with a corresponding correction to increase the income from discontinued operations from $0.06 to $0.07 per basic and diluted share, and certain other reclassifications. These corrections and reclassifications had no effect on the previously published full-year 2006 or 2005 results.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has two products on the market today: Nabi-HB^® [Hepatitis B Immune Globulin (Human)], and Aloprim™ (allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Hepatitis and transplant, Gram-positive bacterial infections and nicotine addiction. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website: http://www.nabi.com.

# # #

(more)

Nabi Biopharmaceuticals Files Form 10-K and Corrects Financial Tables

Page 2 of 3

Nabi Biopharmaceuticals

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except per share data)

	For the Three Months Ended						For the Twelve Months Ended
	December 30, 2006			December 31, 2005			December 30, 2006			December 31, 2005
Revenues	$	30,343		$	26,770		$	89,868		$	94,149
Costs and expenses:
Costs of products sold, excluding amortization of intangible assets		18,096			22,099			61,177			63,642
Royalty expense		510			484			1,535			3,623
Gross margin, excluding amortization of intangible assets		11,737			4,187			27,156			26,884
Selling, general and administrative expense		10,108			11,824			43,076			51,693
Research and development expense		9,671			13,234			37,572			60,906
Amortization of intangible assets		69			131			273			676
Other operating expense, principally freight		98			76			495			348
Impairment of vaccine manufacturing facility		—			19,842			—			19,842
Write-off of manufacturing right		—			2,684			—			2,684
Operating loss		(8,209	)		(43,604	)		(54,260	)		(109,265	)
Interest income		1,232			1,350			4,148			4,094
Interest expense		(928	)		(1,043	)		(3,724	)		(2,523	)
Other expense, net		(367	)		(372	)		(38	)		(483	)
Loss from continuing operations before benefit (provision) for income taxes		(8,272	)		(43,669	)		(53,874	)		(108,177	)
Benefit (provision) for income taxes		10			(15,725	)		162			2,610
Loss from continuing operations		(8,262	)		(59,394	)		(53,712	)		(105,567	)
Discontinued operations
Income (loss) from discontinued operations		4,283			(11,824	)		(4,991	)		(21,180	)
Provision for income taxes		(10	)		(4,361	)		—			(1,702	)
Income (loss) from discontinued operations		4,273			(16,185	)		(4,991	)		(22,882	)
Net loss	$	(3,989	)	$	(75,579	)	$	(58,703	)	$	(128,449	)
Basic and diluted loss per share
Continuing operations	$	(0.13	)	$	(0.99	)	$	(0.88	)	$	(1.76	)
Discontinued operations		0.07			(0.26	)		(0.08	)		(0.39	)
Basic and diluted loss per share	$	(0.06	)	$	(1.25	)	$	(0.96	)	$	(2.15	)
Basic and diluted weighted average shares outstanding		61,473			60,231			60,936			59,862
SUPPLEMENTAL INFORMATION:
Sales by Operating Segment
Biopharmaceutical Products	$	16,644		$	11,367		$	40,093		$	48,231
Antibody Products:
Specialty antibodies		7,019			8,815			26,945			22,936
Non-specific antibodies		6,680			6,588			22,830			22,982
Total antibodies		13,699			15,403			49,775			45,918
Total	$	30,343		$	26,770		$	89,868		$	94,149

(more)

Nabi Biopharmaceuticals Files Form 10-K and Corrects Financial Tables

Page 3 of 3

Nabi Biopharmaceuticals

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, amounts in thousands)

	December 30, 2006		December 31, 2005
Cash and cash equivalents	$	86,227	$	101,762
Marketable securities		32,500		5,172
Restricted cash		805		816
Trade accounts receivable, net		20,377		19,688
Inventories, net		19,260		20,500
Prepaid expenses and other current assets		2,654		3,449
Current assets of discontinued operations		13,341		81,215
Property, plant and equipment, net		88,329		93,865
Intangible assets, net		1,683		1,955
Other assets, net		701		914
Total assets	$	265,877	$	329,336
Trade accounts payable and accrued expenses	$	24,384	$	30,075
Current liabilities of discontinued operations		20,554		16,966
2.875% convertible senior notes, net		109,313		109,145
Non-current liabilities of discontinued operations		—		10,707
Other liabilities		238		616
Stockholders’ equity		111,388		161,827
Total liabilities and stockholders’ equity	$	265,877	$	329,336

Capital expenditures were $2.6 million and $8.5 million for the years ended December 30, 2006 and December 31, 2005, respectively.

Depreciation and amortization expenses from continuing operations were $7.9 million and $10.7 million for years ended December 30, 2006 and December 31, 2005, respectively.

The condensed consolidated balance sheets have been derived from the audited balance sheets. Certain items in the 2005 condensed consolidated financial statements have been reclassified to conform to the current year’s presentation.